Clinical trials: Hypersensitivity
- Condition Hypersensitivity
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Atopic Dermatitis
Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis
A phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter study to evaluate the safety and bioequivalence of Par Pharmaceutical Inc.'s Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus…
- Trial name
- NCT03297502
- Testing
- pimecrolimus cream 1%, Elidel (pimecrolimus) cream 1%
- Volunteers
- 582 people
- Sponsor
- Par Pharmaceutical, Inc.
Acute Bronchial Obstruction, Asthma
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
To determine efficacy and tolerability of inhaled Formoterol vs nebulized Ipatropioum Bromide plus Fenoterol in cumulative sequential doses in asthmatic children (5-<12 years) with acute bronchial obstruction attending emergency…
- Trial name
- NCT00460577
- Testing
- Formoterol fumerate, fenoterol/ipratropium bromide
- Where
- 2 sites in Venezuela
- Volunteers
- 60 people
- Sponsor
- Novartis
Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
- Trial name
- NCT05579730
- Testing
- Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%
- Where
- 4 sites in United States
- Volunteers
- 188 people
- Sponsor
- Bausch & Lomb Incorporated
Rhinitis, Allergic, Perennial
A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis
The purpose of this study is to assess long-term ocular safety of fluticasone furoate nasal spray in adult and adolescent subjects diagnosed with perennial allergic rhinitis.
- Trial name
- NCT00682643
- Testing
- fluticasone furoate nasal spray
- Where
- 56 sites in United States
- Volunteers
- 550 people
- Sponsor
- GlaxoSmithKline
Allergic Conjunctivitis
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
- Trial name
- NCT00432757
- Testing
- Ketotifen with a Contact Lens (generic name not yet established)
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vistakon Pharmaceuticals
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
C1 Esterase Inhibitor Deficiency, Angio Edema
Biomarker for Hereditary AngioEdema Disease
International, multicenter, observational, longitudinal monitoring study to identify, validate and/or monitor Mass Spectrometry (MS)-based biomarker/s for Hereditary Angioedeme (HAE) disease and to test the clinical robustness…
- Conditions
- C1 Esterase Inhibitor Deficiency, Angio Edema, C4 Deficiency, HAE
- Trial name
- BioHAE (NCT03029728)
- Where
- 7 sites in Armenia, Georgia and 5 more
- Volunteers
- 42 people
- Sponsor
- CENTOGENE GmbH Rostock
Asthma
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent…
- Trial name
- NCT03226392
- Testing
- QAW039
- Where
- 142 sites in United States, Brazil and 16 more
- Volunteers
- 704 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)
The aim of the present study is to investigate the efficacy and safety of ciclesonide on lung function and safety. Ciclesonide will be inhaled at one dose level once daily, using an inhaler device with or without spacer.
- Trial name
- NCT00163436
- Testing
- Ciclesonide
- Where
- 66 sites in Canada, France and 4 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Asthma
Study of MAP0010 in Asthmatic Children and Adolescents
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
- Trial name
- NCT00697801
- Testing
- MAP0010 low dose, MAP0010 high dose
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- Allergan
Cow's Milk Protein Allergy
Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain
Damira 2000© is a 100% extensive casein hydrolysate (eHCF). It is formulated to help reverse growth retardation as a result of cow's milk proteins allergy (CMPA), to be well tolerated and to help improve symptoms.Damira 2000 is…
- Trial name
- DELISA (NCT06273371)
- Testing
- Damira 2000 Infant formula
- Where
- 8 sites in Spain
- Volunteers
- 61 people
- Sponsor
- Lactalis
Rhinitis, Allergic, Seasonal
Study Of Perennial Allergic Rhinitis
This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc.
- Trial name
- NCT00358475
- Testing
- GW685698
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Asthma
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma
The purpose of this study is to test if Symbicort (budesonide/formoterol) Turbuhaler is effective in treating asthma when used 'as needed' in patients with milder asthma.
- Trial name
- SYGMA2 (NCT02224157)
- Testing
- budesonode bid + terbutaline 'as needed'
- Where
- 340 sites in Australia, Brazil and 23 more
- Volunteers
- 4,215 people
- Sponsor
- AstraZeneca
Allergic Reaction (IgA) Vasculitis
Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
Hypersensitivity (IgA) vasculitis is a common vascular allergic disease, the cause of which is not yet clear, and may involve infection, immune disorders, heredity and other factors. It belongs to the category of immune diseases.
- Trial name
- NCT07595367
- Testing
- BBD-1 Multi target Immune Enhancement Targeting Agent
- Where
- 2 sites in United States, China
- Volunteers
- 30 people
- Sponsor
- Qifeng Zhang
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Atopic Dermatitis
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.
- Trial name
- NCT04875169
- Testing
- Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Extension Treatment Active Experimental: SHR0302 Dose#1
- Where
- 52 sites in Canada, China
- Volunteers
- 336 people
- Sponsor
- Reistone Biopharma Company Limited
Asthma
A Dose-ranging Study of Fluticasone Furoate (FF)
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma.
- Trial name
- NCT01563029
- Testing
- Fluticasone Furoate, Fluticasone Propionate
- Where
- 139 sites in United States, Bulgaria and 13 more
- Volunteers
- 597 people
- Sponsor
- GlaxoSmithKline
Cow's Milk Allergy
Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy
This is a multicenter, controlled, randomized, prospective, non-inferiority, double blind intervention trial to evaluate the children growth (at 6, 9 and 12 months) using a rice hydrolysed protein formula compared to an…
- Trial name
- GRITO-14 (NCT02405923)
- Testing
- HRF, eHF
- Where
- 5 sites in France, Spain
- Volunteers
- 117 people
- Sponsor
- Laboratorios Ordesa
Dermatitis, Atopic, Pruritus
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population
- Trial name
- NCT06488742
- Testing
- 3% kanuka oil
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nexgen Dermatologics, Inc.
Asthma
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Trial name
- NCT05363670
- Testing
- ARS-1 1 mg, Albuterol MDI, ARS-1 2mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- ARS Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.